Navigation Links
Heart Disease: An Epidemic For Firefighters
Date:3/17/2009

Landmark FEMA Study Results Released

ATLANTA, March 17 /PRNewswire/ -- H. Robert Superko, MD, principal investigator in the landmark FEMA-sponsored study of firefighters aged 40 and over conducted at Saint Joseph's Hospital in Atlanta, released preliminary findings in the world's first study of first responders at risk of suffering sudden death or other significant cardiac events. Firefighters are known to have a three hundred percent increased risk for cardiac disease as compared to other segments of the population.

"Preliminary findings show that one third of firefighters had heart disease that is unrelated to traditional risk factors, such as high cholesterol," says Dr. Superko. "Those results are astounding and point at job duties and environment as the primary determinants for early death in our country's first responders."

Dr. Superko, recognized as a leading expert on lipids, cholesterol and advanced metabolic markets and their contribution to heart disease, and his team performed a comprehensive, scientific battery of sophisticated blood and imaging tests on three hundred firefighters in Gwinnett County, Georgia. Gwinnett County first responders were identified for the study following an emotional report by Fire Chief Steve Rolader, following the sudden death of one of his firefighters from cardiac arrest while fighting a house fire.

"This wasn't the first firefighter in my department to die but I wanted to do something to make it among the last," says Chief Rolader. "This man was 53 years old, in great physical shape and he had no known symptoms of heart disease. We also had lost several newly-retired firefighters to sudden cardiac death. There had to be a way to stop it."

Study volunteers underwent a comprehensive genetic screen of more than a million genes including newly identified KIF6 (statin responsiveness gene) and 9p21 (myocardial
'/>"/>

SOURCE Saint Joseph's Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
4. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
5. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
8. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
9. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3
Breaking Biology News(10 mins):Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2ThermoGenesis Announces National Institute of Health Grant 4576 1ThermoGenesis Announces National Institute of Health Grant 4576 2ThermoGenesis Announces National Institute of Health Grant 4576 3ThermoGenesis Announces National Institute of Health Grant 4576 4MU study finds connection between evolution classroom learning 8764 1MU study finds connection between evolution classroom learning 8764 2Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 1Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 2Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 3Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 4